UCMSCs as Front-line Approach of Treatment for Patients With aGVHD

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 1, 2019

Primary Completion Date

July 18, 2023

Study Completion Date

January 25, 2024

Conditions

Acute-graft-versus-host Disease

Interventions

BIOLOGICAL

Umbilical cord derived mesenchymal stem cell

OTHER

Placebo

Normal saline

Trial Locations (1)

Hospital Ampang, Ampang

All Listed Sponsors

collaborator

Universiti Tunku Abdul Rahman

OTHER

lead

Cytopeutics Sdn. Bhd.

INDUSTRY

NCT03847844 - UCMSCs as Front-line Approach of Treatment for Patients With aGVHD | Biotech Hunter | Biotech Hunter